We are live on ! Find out more
BLFS icon

BioLife Solutions

160 hedge funds and large institutions have $509M invested in BioLife Solutions in 2022 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 73 increasing their positions, 40 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 40

2.45% more ownership

Funds ownership: 84.44%86.89% (+2.5%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

4% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 25

2% less funds holding

Funds holding: 164160 (-4)

36% less capital invested

Capital invested by funds: $797M → $509M (-$288M)

99% less call options, than puts

Call options by funds: $6K | Put options by funds: $524K

Holders
160
Holders Change
-4
Holders Change %
-2.44%
% of All Funds
2.7%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
24
Increased
73
Reduced
40
Closed
25
Calls
$6K
Puts
$524K
Net Calls
-$518K
Net Calls Change
+$419K
Name Holding Trade Value Shares
Change
Change in
Stake
CC
1
Casdin Capital
New York
$104M
BlackRock
2
BlackRock
New York
$67.6M +$17.3M +1,180,523 +32%
Vanguard Group
3
Vanguard Group
Pennsylvania
$29.1M -$1.44M -98,004 -4%
FAM
4
Fred Alger Management
New York
$24.5M -$1.12M -76,258 -4%
Millennium Management
5
Millennium Management
New York
$21.5M +$7.14M +486,631 +45%
GCM
6
Geneva Capital Management
Wisconsin
$20.1M -$50.7K -3,455 -0.2%
State Street
7
State Street
Massachusetts
$17.5M +$3.86M +263,021 +26%
Ameriprise
8
Ameriprise
Minnesota
$14.9M +$111K +7,574 +0.7%
PCM
9
Palisade Capital Management
New Jersey
$12.7M +$5.41M +368,415 +67%
GIM
10
Granahan Investment Management
Massachusetts
$10.5M +$2.17M +147,861 +24%
Invesco
11
Invesco
Georgia
$10.4M -$67K -4,568 -0.6%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$8.07M +$3.21M +218,956 +60%
GS
13
Gagnon Securities
New York
$7.89M +$2.82M +192,173 +51%
TCM
14
TimesSquare Capital Management
New York
$6.73M +$77.8K +5,300 +1%
ZDA
15
Zweig-DiMenna Associates
New York
$6.47M +$1.35M +91,811 +24%
Jennison Associates
16
Jennison Associates
New York
$6.3M +$495K +33,761 +8%
JP Morgan Chase
17
JP Morgan Chase
New York
$6.28M +$226K +15,397 +4%
Morgan Stanley
18
Morgan Stanley
New York
$5.45M +$2.64M +180,032 +84%
Northern Trust
19
Northern Trust
Illinois
$5.02M +$2.35M +160,432 +79%
Fidelity Investments
20
Fidelity Investments
Massachusetts
$4.96M +$937K +63,835 +22%
CRC
21
Curi RMB Capital
Illinois
$4.85M +$381K +25,986 +8%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$4.63M +$784K +53,459 +19%
RIM
23
Ranger Investment Management
Texas
$4.46M -$14.3M -977,462 -75%
PCM
24
Peregrine Capital Management
Minnesota
$4.29M -$3.4K -232 -0.1%
New York State Common Retirement Fund
25
New York State Common Retirement Fund
New York
$4.24M +$1.7M +115,794 +60%

BLFS Hedge Fund Activity: Q2 2022 in Review

160 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in BioLife Solutions (BLFS) for Q2 2022, worth a combined $509M — down 36% from $797M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of BLFS and 24 opened new positions — a net loss of 1 holder — while 40 trimmed existing stakes and 73 added.

The largest buyer was BlackRock, adding an estimated $17.3M. The largest seller was Marshall Wace, exiting entirely with an estimated $20.1M sold.

  • 160 institutional investors held BioLife Solutions (BLFS) as of Q2 2022, down from 164 in Q1 2022.
  • Funds reported $509M of BioLife Solutions stock for Q2 2022, down 36% quarter-over-quarter.
  • 24 funds opened new BioLife Solutions positions in Q2 2022 and 25 closed out, a net change of -1 holder.
  • The largest BioLife Solutions buyer in Q2 2022 was BlackRock, an estimated $17.3M added.
  • The largest BioLife Solutions seller in Q2 2022 was Marshall Wace, an estimated $20.1M sold.

Based on aggregated 13F filings for Q2 2022.